Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Value of SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma

NCT03382522 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT03382522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03382522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Value of SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma
Lead sponsor
University Hospital, Brest
Phase
Observational
Overall status
Completed
Start date
January 1, 2018
Completion date
March 30, 2018
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer